Clinical Trials Logo

Overall Response Rate clinical trials

View clinical trials related to Overall Response Rate.

Filter by:
  • None
  • Page 1

NCT ID: NCT06277024 Recruiting - Clinical trials for Overall Response Rate

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients

NCT ID: NCT01291667 Completed - Adverse Events Clinical Trials

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

HOPES
Start date: May 2009
Phase: Phase 3
Study type: Observational

Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.